Eric L. Simpson, 1 Mark Boguniewicz, 2 Lindsey Finklea, 3 Edward Lain, 4 Luna Sun, 5 Sherry Chen, 6 Robinette Angle, 7 Tracy Cardillo, 8 Fabio P. Nunes, 9 Jonathan I. Silverberg 10
1Oregon Health and Science University, Portland, USA; 2National Jewish Health, Denver, USA; 3RFS Dermatology, San Antonio, USA; 4Sanova Dermatology, Pflugerville, USA; 5Eli Lilly and Company, Indianapolis, USA; 6Tigeread, Somerset, USA; 7Formerly with Eli Lilly and Company, Indianapolis, USA; 8George Washington University, Washington, DC, USA; 9Employed with Eli Lilly and Company at the time of the study

Long-term Efficacy of Baricitinib 2-mg for the Treatment of Atopic Dermatitis in North America

Key Eligibility Criteria

**BREEZE-AD5**

- ≥18 years old and diagnosis of AD for ≥12 months
- History of inadequate response or intolerance to existing corticosteroids (TCS)
- Patients who required rescue therapy at any time during the first 16 weeks
- Patients who did not achieve vIGA-AD ≤3 after Week 16 in BREEZE-AD5

**BREEZE-AD6**

- Patients who required rescue therapy at any time during the first 16 weeks
- Patients who did not achieve vIGA-AD ≤3 after Week 16 in BREEZE-AD5
- Patients who did not achieve vIGA-AD ≤3 after Week 16 in BREEZE-AD6
- Patients who did not achieve vIGA-AD ≤3 after Week 16 in BREEZE-AD6

Assessments and Outcomes

**EASI75 Response Through Week 52 of Treatment With Baricitinib 2-mg**

- **EASI**
  - Mean percent change from baseline to Week 16
  - Proportion of patients achieving EASI75
- **vGADA-AD**
  - Proportion of patients achieving score of 0
- **SCORAD visual analog scale**
  - Mean improvement in SCORAD itch score
- **DLQI**
  - Proportion of patients achieving DLQI score 0

Statistical Analyses

- Data are presented for intent-to-treat population, which included all patients randomized to baricitinib 2-mg in BREEZE-AD5 (N=146) and BREEZE-AD6 (N=146)
- Data were excluded in the following weeks:
  - Weeks 53 and 54 (designated as Week 16 for analysis)
  - Weeks 55 and 52 (designated as Week 16 for analysis)
- Data beyond Week 52 were excluded

RESULTS

| Baseline Characteristics and Disease Activity for BREEZE-AD6 |
|------------------|------------------|
| Age (years)      | 46 (14.5)        |
| Sex               | 0.77 (0.47)      |
| Race (%)          | 58 (30.5)        |
| Duration since AD diagnosis (years) | 5.1 (1.9) |

**BREEZE-AD5a**

- Completed at least 16 weeks of the BREEZE-AD5 treatment period
- Patients who did not achieve vIGA-AD ≤3 at Week 16 (non-responders or partial responders in BREEZE-AD5)
- Patients with vIGA-AD ≤3 after Week 16 in BREEZE-AD5
- Patients who required rescue therapy at any time during the BREEZE-AD5 treatment period
- Completion of full treatment period in BREEZE-AD5s

**BREEZE-AD6a**

- Completed at least 16 weeks of the BREEZE-AD6 treatment period
- Patients who did not achieve vIGA-AD ≤3 at Week 16 (non-responders or partial responders in BREEZE-AD6)
- Patients with vIGA-AD ≤3 after Week 16 in BREEZE-AD6
- Patients who required rescue therapy at any time during the BREEZE-AD6 treatment period
- Completion of full treatment period in BREEZE-AD6s

REFERENCE